Intelligence · Drug directory
Withdrawn Drug Applications
Drugs with withdrawn or discontinued regulatory applications in the US or EU — useful for competitive and label-history research.
Quick answer
Withdrawn applications: NovaPharmaNews tracks 229 pharmaceutical drugs in this segment. Drugs with withdrawn or discontinued regulatory applications in the US or EU — useful for competitive and label-history research.
-
autologous glioma tumor cell lysates (inactivated)
SITOIGANAP
L01XX -
autologous human chondrocytes in vitro expanded
ARTOBEND
M09AX02 -
autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-t)
PROVENGE
L03AX17 -
avacincaptad pegol
IZELVAY
S01XA32 -
bamlanivimab
BAMLANIVIMAB AND ETESEVIMAB FOR COVID-19
-
bardoxolone methyl
IMBARKYD
-
begelomab
BEGEDINA
L04AA35 -
betibeglogene autotemcel
ZYNTEGLO
B06A -
bifikafusp alfa
NIDLEGY
L01XY -
blarcamesine
BLARCAMESINE ANAVEX
N06D -
botulinum toxin type b
NEUROBLOC
M03AX01 -
briakinumab
OZESPA
L04AC09 -
carisbamate
COMFYDE
-
casirivimab
RONAPREVE
J06BD07 -
casopitant
ZUNRISA
-
cediranib maleate
ZEMFIRZA
L01XE32 -
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
CHONDROCELECT
M09AX02 -
colestilan
BINDREN
V03AE -
copanlisib
ALIQOPA
-
covid-19 vaccine (ad26.cov2-s [recombinant])
JCOVDEN (PREVIOUSLY COVID-19 VACCINE JANSSEN)
J07BN02 -
covid-19 vaccine (chadox1-s [recombinant])
VAXZEVRIA (PREVIOUSLY COVID-19 VACCINE ASTRAZENECA)
J07BN02 -
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
COVID-19 VACCINE (INACTIVATED, ADJUVANTED) VALNEVA
J07BX03 -
dasabuvir
EXVIERA
J05AP09 -
depreotide
NEOSPECT
V09IA05
Frequently asked questions
How many withdrawn drugs are listed?
229 drug profiles match this regulatory segment in our published index.
Where does approval data come from?
Profiles combine FDA Drugs@FDA, EMA EPAR references, and regional authority feeds. See our data sources page for attribution.